Tsilionis V, Moustakli E, Dafopoulos S, Zikopoulos A, Sotiriou S, Zachariou A
Metabolites. 2024; 14(12).
PMID: 39728498
PMC: 11678689.
DOI: 10.3390/metabo14120717.
Luo J, Powell J, Ross S, Johnson J, Olopade C, Pinto J
Front Epidemiol. 2024; 3:1241645.
PMID: 38455889
PMC: 10910923.
DOI: 10.3389/fepid.2023.1241645.
Azizbayeva R, Drennen Z, Solanki R, Keshava V, Bhagavatula R, Sareen M
J Community Hosp Intern Med Perspect. 2023; 13(5):61-64.
PMID: 37868669
PMC: 10589043.
DOI: 10.55729/2000-9666.1223.
Pereira L, da Silva M, Germano C, Estevao I, Melo D
Front Med (Lausanne). 2023; 10:1144226.
PMID: 37200963
PMC: 10187638.
DOI: 10.3389/fmed.2023.1144226.
Elia G, Konstantyner T, Nais R, Dos Santos A, Angel A, Braga J
Rev Paul Pediatr. 2023; 41:e2021407.
PMID: 36921171
PMC: 10013992.
DOI: 10.1590/1984-0462/2023/41/2021407.
Developing a mortality risk prediction model using data of 3663 hospitalized COVID-19 patients: a retrospective cohort study in an Egyptian University Hospital.
Kandil S, Tharwat A, Mohsen S, Eldeeb M, Abdallah W, Hilal A
BMC Pulm Med. 2023; 23(1):57.
PMID: 36750802
PMC: 9903412.
DOI: 10.1186/s12890-023-02345-3.
COVID-19 infection and pain in adolescents with sickle cell disease: A case series.
Heyman H, Alberts N, Rees M, Puri L, Frett M, Anghelescu D
EJHaem. 2022; 3(4):1310-1315.
PMID: 36467817
PMC: 9713040.
DOI: 10.1002/jha2.587.
COVID- 19 and sickle cell disease: autopsy findings of three deaths at the 37 Military Hospital, Accra, Ghana.
Attoh S, Sarkodie E, Fatchu R, Benneh-Akwasi Kuma A, Asumanu E, McAddy M
Pan Afr Med J. 2022; 41:332.
PMID: 35865842
PMC: 9268333.
DOI: 10.11604/pamj.2022.41.332.30035.
Low morbidity and mortality with COVID-19 in sickle cell disease: A single center experience.
Ramachandran P, Perisetti A, Kathirvelu B, Gajendran M, Ghanta S, Onukogu I
EJHaem. 2022; 1(2):608-614.
PMID: 35845018
PMC: 9175935.
DOI: 10.1002/jha2.87.
SARS-CoV-2 omicron variant may present with severe sickle cell painful crisis: A report of two cases.
Ali E, Hatim A, Yassin M
Clin Case Rep. 2022; 10(6):e05934.
PMID: 35702620
PMC: 9178402.
DOI: 10.1002/ccr3.5934.
Acute chest syndrome and COVID-19 in hydroxyurea naïve sickle cell disease patient in a low resource setting.
Mawalla W, Nasser A, Jingu J, Joseph H, Mmbaga L, Shija E
EJHaem. 2022; 3(2):507-512.
PMID: 35602245
PMC: 9110990.
DOI: 10.1002/jha2.397.
Coronavirus disease 2019 (COVID-19) in special groups: A single-center experience in sickle cell disease patients in Saudi Arabia.
Al-Ansari R, Abdalla L, Qomawi Y, Alromaih L, Bakkar M, Shilash A
J Family Community Med. 2022; 29(1):71-78.
PMID: 35197731
PMC: 8802730.
DOI: 10.4103/jfcm.jfcm_376_21.
Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature.
Hoogenboom W, Alamuri T, McMahon D, Balanchivadze N, Dabak V, Mitchell W
Blood Rev. 2021; 53:100911.
PMID: 34838342
PMC: 8605823.
DOI: 10.1016/j.blre.2021.100911.
COVID-19 and Hemoglobinopathies: A Systematic Review of Clinical Presentations, Investigations, and Outcomes.
Lee J, Chieng W, Lau S, Tan C
Front Med (Lausanne). 2021; 8:757510.
PMID: 34722593
PMC: 8549676.
DOI: 10.3389/fmed.2021.757510.
Incidence of SARS-COV-2 infection in sickle cell patients presenting with a painful crisis: A 12-month prospective cohort study.
Konte K, Nur E, Tang M, Heijmans J, Van Tuijn C, Biemond B
Int J Lab Hematol. 2021; 44(2):e87-e90.
PMID: 34651455
PMC: 8653089.
DOI: 10.1111/ijlh.13739.
Extrapulmonary manifestations and complications of severe acute respiratory syndrome coronavirus-2 infection: a systematic review.
Cho J, Lee J, Sia C, Koo C, Tan B, Hong W
Singapore Med J. 2021; 64(6):349-365.
PMID: 34544216
PMC: 10335640.
DOI: 10.11622/smedj.2021100.
Sars-CoV-2 Virus Infection May Interfere CD34+ Hematopoietic Stem Cells and Megakaryocyte-Erythroid Progenitors Differentiation Contributing to Platelet Defection towards Insurgence of Thrombocytopenia and Thrombophilia.
Balzanelli M, Distratis P, Dipalma G, Vimercati L, Inchingolo A, Lazzaro R
Microorganisms. 2021; 9(8).
PMID: 34442710
PMC: 8400074.
DOI: 10.3390/microorganisms9081632.
COVID-19 in Saudi Patients With Sickle Cell Disease: A Retrospective Multi-Center Study.
Kashari O, Alghamdi B, Al-Hebshi A, Asiri A, Fallatah E, Alshehri F
Cureus. 2021; 13(8):e17238.
PMID: 34422504
PMC: 8369254.
DOI: 10.7759/cureus.17238.
Potential Implications of a Type 1 Interferon Gene Signature on COVID-19 Severity and Chronic Inflammation in Sickle Cell Disease.
Madany E, Okwan-Duodu D, Balbuena-Merle R, Hendrickson J, Gibb D
Front Med (Lausanne). 2021; 8:679030.
PMID: 34368185
PMC: 8339405.
DOI: 10.3389/fmed.2021.679030.
Individuals with sickle cell disease and sickle cell trait demonstrate no increase in mortality or critical illness from COVID-19 - a fifteen hospital observational study in the Bronx, New York.
Hoogenboom W, Fleysher R, Soby S, Mirhaji P, Mitchell W, Morrone K
Haematologica. 2021; 106(11):3014-3016.
PMID: 34348452
PMC: 8561299.
DOI: 10.3324/haematol.2021.279222.
